By Anthony O. Goriainoff
AstraZeneca plans to list its ordinary shares directly on the New York Stock Exchange as part of a bid to reach a broader mix of investors.
The Anglo-Swedish pharmaceutical giant on Monday said the direct listing would replace the existing listing of its American depository receipts on the Nasdaq.
AstraZeneca said it would continue to be listed, headquartered and tax resident in the U.K., and remained a part of Sweden's OMX Stockholm 30 index.
The company said its move to harmonize its listing structure would support its long-term strategy for sustainable growth.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 29, 2025 02:45 ET (06:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
The articles, information, and content displayed on this webpage may
include materials prepared and provided by third parties. Such
third-party content is offered for informational purposes only and
is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the
accuracy, completeness, timeliness, or reliability of any third-party
content displayed on this site. The views and opinions expressed in
third-party content are those of the respective authors and do not
necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays
in this content, nor for any actions taken in reliance thereon.
Users are advised to exercise their own judgment and seek independent
financial advice before making any decisions based on such content.
The third-party providers of this content are not affiliated with
Morningstar, and their inclusion on this site does not imply any
form of partnership, agency, or endorsement.